8-甲氧基喹唑啉-2,4(1h,3h)-二酮 | 62484-14-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 8-甲氧基喹唑啉-2,4(1h,3h)-二酮
• 中文别名: 8-甲氧基-2,4(1H,3H)-喹唑啉二酮；2,4-二酮-8-甲氧基喹唑啉
• 英文名称: 8-methoxy-1,2,3,4-tetrahydroquinazoline-2,4-dione
• 英文别名: 8-methoxyquinazoline-2,4(1H,3H)-dione；8-methoxy-2,4-quinazolinedione；8-methoxy-2,4-dioxo-1,2,3,4-tetrahydroquinazoline；8-methoxy-1H-quinazoline-2,4-dione；8-Methoxy-1H-chinazolin-2,4-dion；8-Methoxy-2,4-(1H,3H)-chinazolindion；8-methoxy-1H-quinazoline-2,4-dione
• CAS: 62484-14-4
• 化学式: C₉H₈N₂O₃
• mdl: MFCD09954840
• 分子量: 192.174
• InChiKey: JOUZPZZMCYIDOW-UHFFFAOYSA-N

物化性质

• 密度：
  1.322±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8℃，密封保存，并保持干燥。

反应信息

• 作为反应物：
  描述：

  8-甲氧基喹唑啉-2,4(1h,3h)-二酮 在 sodium acetate 、 N,N-二甲基苯胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 101.0h， 生成 2-chloro-8-methoxy-4-<(2-methylphenyl)amino>quinazoline
  参考文献：
  名称：

  Reversible Inhibitors of the Gastric (H+/K+)-ATPase. 5. Substituted 2,4-Diaminoquinazolines and Thienopyrimidines

  摘要：

  Quinazolines bearing a secondary 4-(arylamino) substituent demonstrate an SAR for inhibition of the gastric (H+/K+)-ATPase different from the previously described 3-acylquinolines, suggesting that, although these compounds are also K+-competitive, they probably bind to the enzyme in a different orientation. Compounds bearing a tertiary 4-(arylamino) substituent, however, in particular 4-(N-methylarylamino), appear to possess an SAR quite similar to the 3-acylquinolines. We show that this arises from the effect of the N-methylation, which is to orientate the 4-(arylamino) substituent syn to C-5, analogous to the 3-acylquinolines. Compounds possessing both a 4-(N-methylarylamino) substituent and a 2-(arylamino) substituent proved to be very potent, K+-competitive inhibitors of K+-stimulated ATPase activity with K-i values down to 12 nM. Some compounds also proved to be effective inhibitors of stimulated acid secretion in both the rat and dog when dosed intravenously. However, although a number of these demonstrated activity after oral administration in the dog, the level and variability precluded further evaluation.

  DOI：

  10.1021/jm00014a027
• 作为产物：
  描述：

  2-氨基-3-甲氧基苯甲酸 在 sodium hydroxide 作用下， 以 水 、 溶剂黄146 为溶剂， 以58%的产率得到8-甲氧基喹唑啉-2,4(1h,3h)-二酮
  参考文献：
  名称：

  Substituted quinazoline derivatives for use in gastrointestinal diseases

  摘要：

  2,4-二氨基喹唑啉化合物是H.sup.+ K.sup.+ ATP酶的抑制剂，对基于胃酸分泌过多的胃病的治疗有用。该发明的化合物是2-[2-甲基-4-氟苯基)氨基]-4-(N-甲基苯胺基)喹唑啉。

  公开号：

  US05064833A1
• 作为试剂：
  描述：

  2-氨基-3-甲氧基苯甲酸 、 溶剂黄146 、 Potassium cyanate 、 sodium hydroxide 在 hydrated sodium 、 水 、 8-甲氧基喹唑啉-2,4(1h,3h)-二酮 作用下， 以 水 为溶剂， 反应 2.0h， 生成 8-甲氧基喹唑啉-2,4(1h,3h)-二酮
  参考文献：
  名称：

  Substituted quinazoline derivatives for use in gastrointestinal diseases

  摘要：

  2,4-二氨基喹嗪化合物是H.sup.+ K.sup.+ ATPase酶的抑制剂，可用于治疗基于胃酸分泌过多的胃病。本发明的一种化合物是2-[2-甲基-4-氟苯基)氨基]-4-(N-甲基苯基氨基)喹嗪。

  公开号：

  US05064833A1

文献信息

• [EN] MONO AND BICYCLIC RING BORONIC ACID, ESTER AND SALT COMPOUNDS AS INHIBITORS OF P97 COMPLEX<br/>[FR] COMPOSÉS D'ESTER, DE SEL ET D'ACIDE BORONIQUE À NOYAU MONOCYCLIQUE ET BICYCLIQUE EN TANT QU'INHIBITEURS DE COMPLEXE P97
  申请人：CLEAVE BIOSCIENCES INC

  公开号：WO2016200840A1

  公开（公告）日：2016-12-15

  Monocyclic or bicyclic ring boronic acid or ester compounds having an arylalkyi amine substituent at the 4 position and a substituted 5:6 bicyclic group at the 2 position of the mono or bicyclic ring boronic acid or ester as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the mono or bicyclic boronic acid or ester compounds are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with the Valosin containing protein and p97 bioactivity such as cancer. Formula (I).

  单环或双环硼酸或硼酸酯化合物，在4位具有芳烷基胺取代基，在单环或双环硼酸或硼酸酯的2位具有取代的5:6双环基团，以及在单环或双环硼酸或硼酸酯化合物的其他位置可选地取代有脂肪族、功能性和/或芳香族组分。这些化合物是含有p97的AAA蛋白酶体的抑制剂，并且是治疗与含有Valosin蛋白和p97生物活性相关的疾病的有效药物，如癌症。公式(I)。
• [EN] HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER<br/>[FR] COMPOSÉS HÉTÉROBICYCLO-SUBSTITUÉS-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE POUR LE TRAITEMENT D'UN TROUBLE DU SYSTÈME NERVEUX CENTRAL
  申请人：MERCK SHARP & DOHME

  公开号：WO2014101373A1

  公开（公告）日：2014-07-03

  Disclosed are compounds of heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A-receptor.

  本文披露了异杂双环取代的[1,2,4]三唑并[1,5-c]喹唑啉-5-胺化合物，其具有对A2A受体的特异结合，并可用于定量各种具有与A2A受体结合亲和力的化合物在体内受体位点的占有率。
• [EN] HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES<br/>[FR] COMPOSÉS [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES À SUBSTITUTION HÉTÉROBICYCLIQUE AYANT DES PROPRIÉTÉS D'ANTAGONISTES DU RÉCEPTEUR A2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2014105666A1

  公开（公告）日：2014-07-03

  Disclosed are compounds of Formula Gl (structurally represented): where "RG3" "Rd1" to "Rd4", "n", "m", "p", "W", "X", "Y", and "Z" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

  揭示了Formula Gl（结构表示如下）的化合物：其中“RG3”、“Rd1”至“Rd4”、“n”、“m”、“p”、“W”、“X”、“Y”和“Z”在此处被定义，这些化合物是A2A受体的拮抗剂。本文还披露了所述化合物作为A2a受体拮抗剂在潜在的治疗或预防涉及A2A受体的神经系统疾病和疾病中的用途。本文还披露了包含这些化合物的药物组合物以及这些药物组合物的用途。
• [EN] HETEROBICYCLO-SUBSTITUTED-7-METHOXY-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES<br/>[FR] COMPOSÉS DE 7-MÉTHOXY-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLINE-5-AMINE À SUBSTITUTION HÉTÉROBICYCLO PRÉSENTANT DES PROPRIÉTÉS D'ANTAGONISTE D'A2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2014101120A1

  公开（公告）日：2014-07-03

  Disclosed are compounds of Formulae A defined herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A receptor.

  本文披露了在此定义的A式化合物，其对A2A受体具有特异结合，并可用于定量各种具有与A2A受体结合亲和力的化合物在体内受体位点的占有率。
• [EN] PIPERAZINE-SUBSTITUTED 7-METHOXY-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES<br/>[FR] COMPOSÉS DE 7-MÉTHOXY-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLINE-5-AMINE À SUBSTITUTION PIPÉRAZINE PRÉSENTANT DES PROPRIÉTÉS D'ANTAGONISTE D'A2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2014101113A1

  公开（公告）日：2014-07-03

  Disclosed are compounds of Formula (A), as defined herein, which have binding activity for an A2A-receptor and are believed to be useful for treatment or management of CNS diseases or conditions which can be treated or managed using compounds which have A2A receptor antagonist activity.

  本公开的是本文所定义的Formula (A)的化合物，它们具有与A2A受体的结合活性，并被认为对于治疗或管理可以使用具有A2A受体拮抗活性的化合物来治疗或管理的中枢神经系统疾病或疾况是有用的。